Published in Neurology on September 14, 2004
Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer (2007) 1.81
Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol (2013) 1.56
Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology (2011) 1.41
Late relapse in primary central nervous system lymphoma: clonal persistence. Neuro Oncol (2011) 0.92
Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol (2007) 0.92
Primary CNS lymphoma. Ther Adv Neurol Disord (2009) 0.91
Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma (2012) 0.87
Rituximab in the treatment of non-Hodgkin's lymphoma. Biologics (2008) 0.87
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica (2014) 0.87
Primary CNS lymphoma. Curr Hematol Malig Rep (2014) 0.85
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Neuro Oncol (2009) 0.82
Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol (2013) 0.81
Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma. Clin Cancer Res (2011) 0.80
Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma. Yonsei Med J (2011) 0.80
Current and emerging pharmacotherapies for primary CNS lymphoma. Clin Med Insights Oncol (2012) 0.80
Methotrexate re-challenge for recurrent primary central nervous system lymphoma. J Neurooncol (2014) 0.79
Complete response induced by fotemustine given as single agent in a patient with primary central nervous system non-Hodgkin aggressive lymphoma relapsed after high-dose chemotherapy and autologous stem cell support. Leuk Lymphoma (2011) 0.79
Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas. Brain Tumor Res Treat (2015) 0.78
Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol Ther (2008) 0.78
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology (2005) 0.78
Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade). Indian J Med Paediatr Oncol (2017) 0.75
Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. Oncol Lett (2016) 0.75
Fatal lymphomatoid granulomatosis with primary CNS-involvement in an immunocompetent 80-year-old woman. BMJ Case Rep (2014) 0.75
Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system. Exp Ther Med (2010) 0.75
Salvage therapy for refractory AIDS-related primary central nervous system lymphoma. Case Rep Oncol Med (2012) 0.75
A Regional Multicenter Retrospective Analysis of Patients with Primary Central Nervous System Lymphoma Diagnosed from 2000-2012: Treatment Patterns and Clinical Outcomes. Cureus (2017) 0.75
Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. Onco Targets Ther (2017) 0.75
Primary CNS Lymphoma. J Clin Oncol (2017) 0.75
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Glioblastoma and other malignant gliomas: a clinical review. JAMA (2013) 4.99
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol (2006) 2.99
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol (2007) 2.62
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res (2005) 2.46
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Brain metastases. Neurol Clin (2003) 2.44
EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal (2009) 2.23
Patterns of care in elderly glioblastoma patients. Ann Neurol (2008) 2.17
Association between incident cancer and subsequent stroke. Ann Neurol (2015) 2.13
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys (2009) 2.07
Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci (2003) 1.99
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology (2005) 1.91
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer (2004) 1.81
Primary ocular lymphoma: clinical features, diagnosis, and treatment. Clin Lymphoma (2003) 1.77
Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol (2006) 1.74
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer (2005) 1.69
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Intracranial dural metastases. Cancer (2009) 1.59
International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59
Advancing the treatment of malignant glioma: act local, think global. Cancer Invest (2004) 1.59
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol (2009) 1.58
Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol (2013) 1.54
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res (2006) 1.53
Chemotherapy for brain tumors--a new beginning. N Engl J Med (2005) 1.49
Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol (2004) 1.48
Multifocal stroke from tumor emboli. Arch Neurol (2009) 1.48
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
Methotrexate area under the curve as a prognostic factor in primary central nervous system lymphoma treated with immunochemoradiotherapy. Leuk Lymphoma (2011) 1.45
Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol (2005) 1.44
Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology (2007) 1.43
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol (2003) 1.41
Maintenance therapy for central nervous system lymphoma with rituximab. Leuk Lymphoma (2009) 1.39
Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol (2003) 1.39
Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol (2007) 1.37
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol (2008) 1.37
Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol (2007) 1.36
Therapeutic challenges in primary CNS lymphoma. Lancet Neurol (2009) 1.36
Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol (2008) 1.36
Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center Experience (1997-2007). Cancer (2009) 1.35
Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol (2005) 1.35
Herpes simplex encephalitis in patients with cancer. J Neurooncol (2011) 1.32
Glioblastoma: molecular analysis and clinical implications. Annu Rev Med (2012) 1.31
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol (2008) 1.31
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol (2012) 1.27
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25
Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol (2011) 1.25
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J Clin Oncol (2009) 1.22
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro Oncol (2002) 1.20
Primary dural lymphomas: a review. Neurosurg Focus (2006) 1.19
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol (2008) 1.18
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep (2013) 1.16
Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer (2005) 1.15
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study. Neurology (2004) 1.15
Primary dural lymphomas: a clinicopathologic study of treatment and outcome in eight patients. Neurology (2006) 1.14
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Cancer (2010) 1.11
Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol (2006) 1.11
An update on primary central nervous system lymphoma. Hematol Oncol Clin North Am (2006) 1.11
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2010) 1.08
Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer (2012) 1.08
Primary central nervous system lymphoma. Neurol Clin (2007) 1.07
The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol (2008) 1.07
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist (2010) 1.05
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro Oncol (2012) 1.04
Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res (2011) 1.04
Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg (2002) 1.03
Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme. Neurology (2007) 1.02
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol (2006) 1.02
Central nervous system lymphoma. Hematology Am Soc Hematol Educ Program (2002) 1.02
Current management of metastatic brain disease. Neurotherapeutics (2009) 1.01
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas. Neuro Oncol (2011) 1.00